Literature DB >> 21058170

Hepatitis B vaccination of male neonates and autism diagnosis, NHIS 1997-2002.

Carolyn M Gallagher1, Melody S Goodman.   

Abstract

Universal hepatitis B vaccination was recommended for U.S. newborns in 1991; however, safety findings are mixed. The association between hepatitis B vaccination of male neonates and parental report of autism diagnosis was determined. This cross-sectional study used weighted probability samples obtained from National Health Interview Survey 1997-2002 data sets. Vaccination status was determined from the vaccination record. Logistic regression was used to estimate the odds for autism diagnosis associated with neonatal hepatitis B vaccination among boys age 3-17 years, born before 1999, adjusted for race, maternal education, and two-parent household. Boys vaccinated as neonates had threefold greater odds for autism diagnosis compared to boys never vaccinated or vaccinated after the first month of life. Non-Hispanic white boys were 64% less likely to have autism diagnosis relative to nonwhite boys. Findings suggest that U.S. male neonates vaccinated with the hepatitis B vaccine prior to 1999 (from vaccination record) had a threefold higher risk for parental report of autism diagnosis compared to boys not vaccinated as neonates during that same time period. Nonwhite boys bore a greater risk.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21058170     DOI: 10.1080/15287394.2010.519317

Source DB:  PubMed          Journal:  J Toxicol Environ Health A        ISSN: 0098-4108


  20 in total

1.  A two-phase study evaluating the relationship between Thimerosal-containing vaccine administration and the risk for an autism spectrum disorder diagnosis in the United States.

Authors:  David A Geier; Brian S Hooker; Janet K Kern; Paul G King; Lisa K Sykes; Mark R Geier
Journal:  Transl Neurodegener       Date:  2013-12-19       Impact factor: 8.014

Review 2.  Aluminum in the central nervous system (CNS): toxicity in humans and animals, vaccine adjuvants, and autoimmunity.

Authors:  C A Shaw; L Tomljenovic
Journal:  Immunol Res       Date:  2013-07       Impact factor: 2.829

3.  The Novel Potential Therapeutic Utility of Montelukast in Alleviating Autistic Behavior Induced by Early Postnatal Administration of Thimerosal in Mice.

Authors:  Lobna A Abdelzaher; Ola A Hussein; I E M Ashry
Journal:  Cell Mol Neurobiol       Date:  2020-04-17       Impact factor: 5.046

Review 4.  Environmental chemical exposures and autism spectrum disorders: a review of the epidemiological evidence.

Authors:  Amy E Kalkbrenner; Rebecca J Schmidt; Annie C Penlesky
Journal:  Curr Probl Pediatr Adolesc Health Care       Date:  2014-09-05

5.  Ancestry of pink disease (infantile acrodynia) identified as a risk factor for autism spectrum disorders.

Authors:  Kerrie Shandley; David W Austin
Journal:  J Toxicol Environ Health A       Date:  2011

6.  Discovering disease associations by integrating electronic clinical data and medical literature.

Authors:  Antony B Holmes; Alexander Hawson; Feng Liu; Carol Friedman; Hossein Khiabanian; Raul Rabadan
Journal:  PLoS One       Date:  2011-06-23       Impact factor: 3.240

7.  The plausibility of a role for mercury in the etiology of autism: a cellular perspective.

Authors:  Matthew Garrecht; David W Austin
Journal:  Toxicol Environ Chem       Date:  2011-05-20       Impact factor: 1.437

8.  Administration of thimerosal to infant rats increases overflow of glutamate and aspartate in the prefrontal cortex: protective role of dehydroepiandrosterone sulfate.

Authors:  Michalina Duszczyk-Budhathoki; Mieszko Olczak; Malgorzata Lehner; Maria Dorota Majewska
Journal:  Neurochem Res       Date:  2011-10-21       Impact factor: 3.996

9.  Evaluation of regression in autism spectrum disorder based on parental reports.

Authors:  Janet K Kern; David A Geier; Mark R Geier
Journal:  N Am J Med Sci       Date:  2014-01

10.  Toward a theory of childhood learning disorders, hyperactivity, and aggression.

Authors:  Anthony R Mawson
Journal:  ISRN Psychiatry       Date:  2012-09-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.